Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics: BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG “Failure ; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy. Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer.

Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics: ? BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG "Failure?; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy.? Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer

Of the three types of bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) is the most common form and is diagnosed in over 70% of cases. This issue of the Urologic Clinics focuses on NMIBC and includes articles on periopertive chemotherapy, office fulguration, TURBT, surveillance strategies, and radiation therapy in type-1 tumors.

The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.

Dr. Holzbeierlein has created an issue devoted to the current knowledge and best practice of Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. Top expert authors have written clinical reviews on the following topics: Current Staging Strategies for Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma; Neoadjuvant Chemotherapy for MIBC and Upper Tract UCC; Bladder Preservation Therapy for MIBC; Pre-Operative and Intraoperative Optimization of the Cystectomy Patient; Robotic Cystectomy; Robotic Nephroureterectomy; Organ Sparing Cystectomy; Lymphadenectomy for MIBC and Upper Tract UCC; ERAS Pathways; Follow-up Management of Cystectomy Patients; Quality of Life after Cystectomy; Endoscopic Approaches to Upper Tract UCC; Adjuvant Therapy in MIBC and Upper Tract UCC; and Immunotherapy in MIBC and Upper Tract UCC. The urologist will have the clinical information he or she needs to treat these patients so as to optimize outcomes.

Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses the latest clinical updates in Male Infertility. Expert authors have contributed clinical review articles on the following topics: Cutting edge evaluation in male infertility; Optimal endocrine evaluation and treatment; Sperm extraction in obstructive azoospermia: What’s next; FNA vs. microTESE; ROSI (round spermatid injection); Reproductive Urology in the context of an IVF practice; Care delivery in male infertility; Qualitative research in male infertility; Male Infertility & Somatic Health; DNA fragmentation: Does testicular sperm make sense; CRISPR & Genetics of Male Infertility after whole genome sequencing; Transgenerational epigenetics: A window into paternal health influences on offspring; Spermatogonial Stem Cell Culture in oncofertility; Personalized medicine for the infertile male; and Male Infertility & The future of IVF. Readers will come away with the clinical information they need to improve outcomes in patients with infertility.